First early-detection blood test for Parkinson's shows promise

A test that profiles molecular biomarkers in blood could become the first accurate diagnostic test for Parkinson's disease, new research shows.

The screen relies on changes in dozens of small molecules in serum. These "metabolomic" alterations form a unique pattern in people with Parkinson's disease, according to a team led by researchers at the Weill Cornell Medical College in New York City.

They published the findings in the journal Brain.

"A reliable blood test for Parkinson's disease would revolutionize not only the care of people with this debilitating illness, it would facilitate research as well," notes study senior author Dr. M. Flint Beal, chairman and Anne Parrish Titzell Professor of Neurology at Weill Cornell Medical College, and neurologist-in-chief at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

According to the National Parkinson Foundation, an estimated 1.5 million Americans have the neurodegenerative disease, and 60,000 new cases are diagnosed each year. Actor Michael J. Fox, boxer Muhammad Ali, and former U.S. Attorney General Janet Reno all suffer from Parkinson's, which strikes men and women in roughly equal numbers.

"Right now, a Parkinson's diagnosis is made solely on a clinical review of symptoms -- we have no biologic test," notes Dr. Beal. At best, a symptom-based screen is still only 90 percent accurate, he adds.

"That can cause real problems, because that remaining 10 percent of patients -- who may have look-alike conditions such as multi-system atrophy or progressive supranuclear palsy -- end up getting treated with Parkinson's drugs," Dr. Beal says. "These medicines may appear to help them a little while, but in the meantime, they haven't been getting the treatment that's necessarily best for them."

An early-detection test would also be enormously useful in tracking the health of patients who may be at higher risk for Parkinson's, such as those with a family history of the disease.

Finally, the integrity of clinical trials is undermined by the lack of an accurate screen, Dr. Beal notes. "Every time you do a clinical trial into Parkinson's and you have patients that are misdiagnosed, it enters 'noise' into the analysis, skewing the results. A truly reliable test could help eliminate that," the researcher notes.

That's why encouraging results for the new test -- based on a patient's "metabolomic profile" -- are so important.

Metabolomics is the study of changes in thousands of distinct, very small molecules found in body fluids or tissues. "Anytime you have a genetic or environmental perturbation, these molecules are altered in specific ways," Dr. Beal explains.

Because Parkinson's treatment could itself trigger some of these alterations, the researchers first compared metabolomic patterns in the blood of Parkinson's patients who were not undergoing treatment versus those who were medicated. "That gave us a 'medication-free' profile that we could use going forward," Dr. Beal explains.

In the next stage of the research, the team compared blood samples from 66 patients with Parkinson's disease against 25 healthy controls (most of whom were the patients' spouses). The metabolomic analysis included over 2,000 small molecules found in the blood.

"We discovered a clear differentiation between the metabolomic profiles of the Parkinson's disease patients versus those of the controls," Dr. Beal says. "No one molecule was definitive, but a pattern of about 160 compounds emerged that was highly specific to Parkinson's patients."

The significance of many individual compounds to the disease remains unknown and will be the focus of future study. But changes in a few well-known metabolites linked to oxidative stress were clearly linked to Parkinson's. These included low levels of the antioxidant uric acid; an increase in blood levels of another antioxidant, glutathione; and increased levels of a marker for oxidative damage called 8-OHdG.

"Together, these and other compounds were arranged into a metabolomic pattern that identified Parkinson's disease with great accuracy," Dr. Beal says.

He stressed that more work needs to be done to validate the finding, and a test that might be used routinely by doctors is still a few years away.

"We are currently enlarging the sample size and studying people at serial intervals, to see if this test might also serve as a benchmark for disease progression," Dr. Beal says. "We are also looking at people who carry a gene for a familial form of Parkinson's, but who do not have the illness now. We hope to track them over time to see if this metabolomic profile is predictive of disease onset."

If those data prove as promising as this early trial, an early-detection blood test for Parkinson's disease could someday become a reality. According to Dr. Beal, "That would be a big step forward for both the treatment and the study of this devastating illness."

Source: New York- Presbyterian Hospital

Related stories:

Biosensor for measuring stress in cells
Cancer, nervous system disorders such as Parkinson’s disease, cardiovascular disorders and old age have one thing in common: Both in afflicted tissue and in aging cells, scientists have observed oxidative changes in important biomolecules. These are caused by reactive oxygen molecules, including the notorious “free radicals” that are formed as a by-product of cellular respiration and attack cellular proteins, nucleic and fatty acids.
Seeing Alzheimer's amyloids
In an important step toward demystifying the role protein clumps play in the development of neurodegenerative disease, researchers have created a stunning three-dimensional picture of an Alzheimer’s peptide aggregate using electron microscopy.
Cell's 'power plant' genes raise vision disorder risk
Genetic variation in the DNA of mitochondria – the “power plants” of cells – contributes to a person’s risk of developing age-related macular degeneration (AMD), Vanderbilt investigators report May 7 in the journal PLoS ONE.
'Nanodrop' Test Tubes Created with a Flip of a Switch
Researchers at the National Institute of Standards and Technology have demonstrated a new device that creates nanodroplet “test tubes” for studying individual proteins under conditions that mimic the crowded confines of a living cell. “By confining individual proteins in nanodroplets of water, researchers can directly observe the dynamics and structural changes of these biomolecules,” says physicist Lori Goldner, a coauthor of the paper published in Langmuir.
First diagnostic test for Alzheimer's and Parkinson's disease on the horizon
A new blood test that can give an early diagnosis of neurodegenerative disease and distinguish between Parkinson’s and Alzheimer’s disease could be launched this summer, reports Marina Murphy in SCI’s Chemistry & Industry magazine.
Stem cell breakthrough offers diabetes hope
Scientists have discovered a new technique for turning embryonic stem cells into insulin-producing pancreatic tissue in what could prove a significant breakthrough in the quest to find new treatments for diabetes.
Researchers link 11 genetic variations to type 2 diabetes
Mathematicians at Michigan Technological University have developed powerful new tools for winnowing out the genes behind some of humanity’s most intractable diseases.
Spit tests may soon replace many blood tests
One day soon patients may spit in a cup, instead of bracing for a needle prick, when being tested for cancer, heart disease or diabetes. A major step in that direction is the cataloguing of the “complete” salivary proteome, a set of proteins in human ductal saliva, identified by a consortium of three research teams, according to an article published today in the Journal of Proteome Research. Replacing blood draws with saliva tests promises to make disease diagnosis, as well as the tracking of treatment efficacy, less invasive and costly.

News discussion:

Medicine & Health news